This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q22.6 | Special Copayment Reduction: V146 (rare disease Special Copayment Reduction) |
| B. Synonyms | Hypoplastic Right Heart Syndrome (HRHS), hypoplastic right ventricle, right-sided analogue of HLHS |
| C. Adult onset | Likelihood of first presentation in adulthood: very low — a ductus-dependent cyanotic congenital heart disease diagnosed in the neonatal period, treated with staged Fontan surgery. Patients who survive into adulthood after the Fontan procedure are managed in ACHD clinics. Fontan-related complications (liver disease, protein-losing enteropathy, arrhythmias) sometimes first appear in adulthood. |
| 1. History | 1952 term HRHS established → right-sided analogue of HLHS. Advances in Glenn (1952), Fontan (1968), and TCPC (1988) surgery form the basis of treatment. Introduction of PGE1, advances in percutaneous pulmonary valve perforation. |
| 2. Causes | Spectrum of malformations with underdeveloped right ventricle: PA/IVS, severe tricuspid atresia, severe Ebstein anomaly, DIRV. Right ventricle cannot eject into the pulmonary artery → functional single ventricle (left ventricle). Without PGE1, death upon ductal closure. |
| 3. Genetics | Follows the genetics of the underlying malformation. Noonan syndrome (PTPN11, etc.): severe PS → HRHS. Rarely associated with CHARGE syndrome. CMA and Noonan panel testing recommended. |
| 4. General epidemiology | About 1 in 5,000–10,000 live births (including PA/IVS + tricuspid atresia). Less frequent than HLHS. Candidates for functional single-ventricle Fontan surgery. Korea Q22.6, Special Copayment Reduction V146. |
| 5. Pathophysiology | Right ventricle cannot eject into the pulmonary artery → functional single ventricle (left ventricle). Pulmonary blood flow = dependent on PDA/BT shunt. Left ventricle supports systemic + pulmonary circulation → cyanosis. After Fontan, passive pulmonary circulation → low cardiac output, organ congestion. |
| 6. Symptoms | Neonates: cyanosis, worsening upon ductal closure (PGE1 essential). After stage 1: persistent cyanosis (SpO2 75–85%). After Fontan: exercise intolerance, abdominal distension, edema, arrhythmias, PLE symptoms. |
| 7. Signs | Cyanosis, reduced oxygen saturation. No murmur or a continuous murmur. Echocardiography: right ventricular size and function, tricuspid valve, pulmonary artery. Cardiac MRI: single-ventricle function, Fontan circuit. Cardiac catheterization: PVR. |
| 8. Screening | Neonatal CCHD oxygen saturation screening. Prenatal fetal echocardiography (underdeveloped right ventricle, tricuspid/pulmonary artery abnormalities). Planned delivery at a specialty center upon prenatal diagnosis. |
| 9. Diagnosis | Echocardiography (right ventricular size/function, tricuspid valve, pulmonary valve). Cardiac CTA (pulmonary artery branches, PDA). Cardiac catheterization (PVR, indications for Fontan surgery). Genetic testing (CMA, Noonan/CHARGE panel). |
| 10. Treatment | If the right ventricle can grow: biventricular surgical pathway (percutaneous perforation → biventricular repair). Single-ventricle pathway: BT shunt → BDG → Fontan (TCPC). PGE1 (to maintain the ductus before surgery). After Fontan: management of anticoagulation, arrhythmias, PLE. |
| 11. Prognosis | Survival after Fontan 70–85% at 5 years, 75–90% at 10 years. HRHS has a better prognosis than HLHS (the left ventricle supports the systemic circulation). Fontan complications (FALD, PLE, arrhythmias) are a long-term challenge. |
| 12. Prevention | Prenatal diagnosis → delivery at a specialty center. Immediate PGE1. After Fontan, regular follow-up at an ACHD specialty center (liver, single ventricle, arrhythmias, anticoagulation). Multidisciplinary management of syndromes such as Noonan. |
| 13. References | List of 10 key references |
Hypoplastic Right Heart Syndrome (HRHS) is an umbrella term for a spectrum of congenital heart diseases in which the right ventricle and related structures (tricuspid valve, pulmonary valve, right ventricular myocardium) are globally underdeveloped so that the right ventricle alone cannot sustain the systemic circulation. The term was first used in 1952 by Ravitch and Taussig and later developed into a concept encompassing the various malformations that cause a hypoplastic right ventricle.
The conceptual origin of HRHS is similar to that of Hypoplastic Left Heart Syndrome (HLHS). HLHS was systematized in 1952 by Noonan and Noonan, and HRHS is recognized as its right-sided analogue. HRHS is not a single disease but encompasses a spectrum of malformations including pulmonary atresia with intact ventricular septum (PA/IVS), severe tricuspid atresia, severe Ebstein anomaly, and double-inlet right ventricle (DIRV).
The history of treatment is largely shared with that of tricuspid atresia and pulmonary atresia. Advances in the Glenn procedure in 1952, the Fontan procedure in 1968, and TCPC in 1988 formed the basis of HRHS treatment. Percutaneous pulmonary valve perforation (radiofrequency perforation) and balloon valvuloplasty made a biventricular surgical pathway possible in HRHS patients with right ventricular growth potential.
Standardization of the staged Fontan surgical pathway (BDG→Fontan) has become the standard of treatment for all functional single-ventricle congenital heart diseases, including HRHS. Since the 2000s, advances in neonatal intensive care, extracorporeal life support (ECMO), and heart transplantation have improved the chances of survival even in the most severe HRHS.
Hypoplastic right heart syndrome is not a single malformation but a spectrum of various causative malformations, each with a different cause. What they have in common is that the right ventricle did not receive sufficient flow stimulation during development, or did not develop normally because of valve malformations.
Main causative malformations: pulmonary atresia with intact ventricular septum (PA/IVS): the right ventricle cannot eject blood into the pulmonary artery, so there is no developmental stimulus and a small right ventricle forms. Severe tricuspid atresia: the tricuspid valve is completely closed, so there is no inflow into the right ventricle and the right ventricle becomes extremely small. Severe tricuspid stenosis: tricuspid inflow is restricted, resulting in poor right ventricular development. Severe Ebstein anomaly: corresponds to HRHS when the functional right ventricular size is extremely small. Double-inlet right ventricle (DIRV): a very rare form.
Genetic causes follow the genetics of the underlying malformation. HRHS with PA/IVS: 22q11.2 deletion is rarely present. Progression to HRHS in severe pulmonary stenosis with Noonan syndrome. With tricuspid atresia: see the previous section. Variants in cardiac transcription factor genes such as GATA4, NKX2.5, and TFAP2B are rarely reported in isolated HRHS cases.
Because hypoplastic right heart syndrome is a heterogeneous spectrum of malformations, its genetics also varies with the underlying malformation. Genetic causes specific to isolated HRHS are not well known to date. The genetics of the underlying malformation (PA/IVS, tricuspid atresia, Ebstein anomaly, etc.) applies.
In Noonan syndrome (variants in PTPN11, SOS1, RAF1, etc.), severe pulmonary stenosis sometimes develops and progresses to HRHS. Noonan syndrome is inherited in an autosomal dominant manner, and the familial recurrence rate is high. In CHARGE syndrome (CHD7 variants, autosomal dominant), HRHS rarely accompanies complex congenital heart disease.
In all HRHS patients, chromosomal microarray (CMA), 22q11.2 deletion FISH, and gene panel testing for clinically suspected syndromes (Noonan, CHARGE, etc.) are recommended. Genetic test results are important for family counseling, recurrence risk assessment, and management of noncardiac complications.
The exact incidence of hypoplastic right heart syndrome is difficult to determine, because HRHS is not a single diagnosis but a spectrum of malformations. The incidence of the entire HRHS spectrum including PA/IVS and tricuspid atresia is estimated at about 1 in 5,000–10,000 live births.
In Korea, it is classified under code Q22.6 and is eligible for Special Copayment Reduction V146. HRHS is an important component of functional single-ventricle congenital heart disease and accounts for a considerable proportion of patients who are candidates for the staged Fontan surgical pathway. HRHS-related malformations are included among the patients who undergo Fontan surgery each year at specialized pediatric cardiac surgery centers in Korea.
HRHS is the right-sided analogue of HLHS, but its incidence is lower than that of HLHS. HLHS accounts for about 2–3% of all congenital heart disease, whereas HRHS is relatively rare. However, because the pathophysiology and treatment principles of HRHS have much in common with HLHS, they are studied and managed together as functional single-ventricle congenital heart disease.
The core pathophysiology of hypoplastic right heart syndrome is that the right ventricle cannot adequately eject blood into the pulmonary artery, establishing functional single-ventricle physiology (the left ventricle supports both the systemic and pulmonary circulations). This is symmetric to HLHS, in which the left ventricle is underdeveloped and the right ventricle alone supports all circulation.
Dependence of pulmonary blood flow: because the right ventricle cannot eject blood into the pulmonary artery, pulmonary blood flow depends on the ductus arteriosus (PDA) or a surgically created shunt (BT shunt). When the ductus closes, pulmonary blood flow is lost and severe hypoxemia develops.
Mixing at the atrial level: oxygenated blood from the left atrium and venous blood entering from the right atrium through an ASD/PFO mix in the left ventricle and are sent to the systemic and pulmonary circulations. This mixing lowers systemic oxygen saturation, causing cyanosis.
Fontan physiology: after staged Fontan surgery, systemic venous blood flows directly into the pulmonary artery without a ventricular pump. Because of the passive pulmonary circulation, a structurally low cardiac output is inherent. Fontan-related long-term complications (liver disease, protein-losing enteropathy, arrhythmias, thrombosis) accumulate over time.
Symptoms of hypoplastic right heart syndrome vary with the severity of the underlying malformation and the surgical stage. Neonatal period: ductus-dependent cyanosis is characteristic. When the ductus closes after birth, sudden worsening of cyanosis, tachypnea, hyperpnea, inability to feed, metabolic acidosis, and shock occur. Maintaining the ductus with immediate PGE1 administration is the first emergency measure.
Symptoms by surgical stage: after stage 1 surgery (BT shunt or PA banding): a steady level of cyanosis (SpO2 about 75–85%) persists, but the infant remains able to feed. After stage 2 (BDG): cyanosis improves to some degree but does not resolve completely. Dyspnea on exertion. After stage 3 (Fontan): cyanosis decreases markedly, but exercise intolerance persists due to limited cardiac output. Fontan-related long-term complications gradually appear.
Adult Fontan patients: chronic exercise intolerance, fatigue, abdominal distension (hepatic congestion), lower-limb edema, palpitations (arrhythmias), reduced urine output (low cardiac output). With protein-losing enteropathy, chronic diarrhea, severe edema, and ascites appear.
The physical findings of neonatal HRHS are characterized by cyanosis and reduced oxygen saturation. Murmurs vary with the underlying malformation, and in simple PA/IVS there may be no murmur. A continuous murmur due to the ductus arteriosus is sometimes heard.
ECG: varies with the underlying malformation. Left axis deviation and left ventricular hypertrophy in tricuspid atresia. Right ventricular hypertrophy in PA/IVS (reflecting high pressure within the right ventricle). Chest X-ray: decreased pulmonary vascular markings; heart size varies with the malformation. Echocardiography: right ventricular size (tricuspid annulus Z-score, right ventricular volume measurement), tricuspid function, pulmonary valve status, atrial defect, presence of the ductus arteriosus. Cardiac MRI: quantification of single-ventricle function, assessment of the Fontan circuit. Cardiac catheterization: measurement of pulmonary vascular resistance (to determine the indication for Fontan surgery).
HRHS is a cyanotic congenital heart disease and a major target of neonatal CCHD oxygen saturation screening (SpO2 < 95%). On prenatal fetal echocardiography (18–22 weeks of gestation), reduced right ventricular size, underdevelopment or atresia of the tricuspid valve, and pulmonary valve abnormalities suggest HRHS.
When HRHS is diagnosed prenatally, delivery is planned before birth at a hospital with a specialized pediatric cardiology team, and a system for immediate PGE1 administration and echocardiographic confirmation at birth is prepared. When Noonan syndrome or another genetic syndrome is suspected, prenatal evaluation including genetic testing is performed.
Diagnosis is based on echocardiography, which precisely identifies the type of HRHS (PA/IVS, tricuspid atresia, Ebstein anomaly, etc.) and assesses right ventricular size and function (tricuspid annulus Z-score, right ventricular volume), tricuspid function, pulmonary valve status, atrial defect, and great vessel connections.
Cardiac CT angiography (CTA): assessment of pulmonary artery branch size, sources of pulmonary blood flow (PDA, BT shunt), coronary artery abnormalities, and associated malformations. Cardiac MRI: quantification of single-ventricle function, assessment of the circuit after Fontan surgery. Cardiac catheterization: measurement of pulmonary vascular resistance (PVR) and pulmonary artery pressure, assessment of Fontan candidacy, confirmation of right ventricle-dependent coronary circulation (with PA/IVS). Genetic testing: CMA, 22q11.2 FISH, Noonan/CHARGE syndrome panel.
HRHS treatment chooses between a biventricular surgical pathway and a single-ventricle Fontan surgical pathway depending on right ventricular size and function.
Biventricular surgical pathway (biventricular repair): when the right ventricle has growth potential (tricuspid annulus Z-score > -2 to -3 or above, right ventricle capable of sufficient development). In PA/IVS, percutaneous pulmonary valve perforation + balloon valvuloplasty opens the right ventricular outflow tract and allows the right ventricle to grow. Later, once the right ventricle has grown sufficiently, conversion to biventricular repair is possible. The long-term advantage of biventricular repair is that Fontan-related complications can be avoided.
Single-ventricle Fontan surgical pathway: when the right ventricle is underdeveloped or biventricular repair is not possible, the same three-stage Fontan surgical pathway as in tricuspid atresia is followed. ① BT shunt (increasing pulmonary blood flow) ② BDG ③ Fontan (TCPC). The lower the pulmonary vascular resistance, the better the results of Fontan surgery (criterion PVR < 2–3 Wood units).
PGE1 maintenance: continuous intravenous PGE1 to maintain ductus-dependent pulmonary blood flow until surgery. Neonatal intensive care: oxygenation, metabolic correction, ventilator support. Post-Fontan management: anticoagulation (warfarin or NOAC), targeted therapy for pulmonary hypertension (sildenafil, etc.), arrhythmia management, treatment of protein-losing enteropathy (high-protein diet, heparin, budesonide, evaluation for heart-lung transplantation).
The prognosis of HRHS varies with the severity of the underlying malformation, choice of surgical pathway, pulmonary vascular resistance, and single-ventricle function. After staged Fontan surgery, 5-year survival for HRHS-related malformations is about 70–85% at specialty centers. 10-year survival after Fontan surgery is about 75–90%.
HRHS vs HLHS comparison: HRHS tends to show an overall better prognosis than HLHS. This is because the left ventricle, as the functional ventricle, can sustain the systemic circulation for a long time. Unlike HLHS, in which systemic right ventricular failure progresses over the long term when the right ventricle serves as the systemic ventricle, in HRHS the left ventricle supports the systemic circulation, so long-term ventricular function is preserved relatively longer.
Fontan-related complications accumulate over time, and Fontan-associated liver disease (FALD), protein-losing enteropathy (PLE), arrhythmias, and thrombosis are the main causes of long-term morbidity and mortality. Regular follow-up and early management of complications at an ACHD specialty center determine the prognosis.
There is no established method for preventing the occurrence of HRHS. Early diagnosis through prenatal fetal echocardiography and neonatal CCHD screening is the best preventive strategy. With prenatal diagnosis, the delivery location, immediate PGE1 administration, and the staged surgical pathway are planned in advance.
After staged Fontan surgery, patients are regularly managed at an ACHD specialty center for the following: liver function (liver ultrasound, AFP, liver biopsy), single-ventricle function (cardiac MRI), arrhythmias (Holter, ECG), anticoagulation management, pulmonary vascular resistance follow-up, renal function, and nutritional status (surveillance for PLE). Because cardiac output is limited in Fontan physiology, individualized guidance is needed for strenuous exercise. When Noonan syndrome or another syndrome is present, multidisciplinary management of noncardiac complications is carried out in parallel.
Fyler DC, Buckley LP, Hellenbrand WE, Cohn HE. Report of the New England Regional Infant Cardiac Program. Pediatrics. 1980;65(2 Pt 2):375-461. PMID: 7354286.
Freedom RM, Anderson RH, Perrin D. The significance of morphologic heterogeneity of the ventricular septal defect in complex congenital heart disease: a 3-dimensional perspective. J Am Coll Cardiol. 2005;46(7):1307-1308. DOI: 10.1016/j.jacc.2005.07.038. PMID: 16198848.
d'Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116(11 Suppl):I157-I164. DOI: 10.1161/CIRCULATIONAHA.106.679902. PMID: 17846311.
Rychik J, Atz AM, Celermajer DS, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019;140(6):e234-e284. DOI: 10.1161/CIR.0000000000000696. PMID: 31256636.
Ohye RG, Sleeper LA, Mahony L, et al. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med. 2010;362(21):1980-1992. DOI: 10.1056/NEJMoa0912461. PMID: 20505177.
Bridges ND, Lock JE, Castaneda AR. Baffle fenestration with subsequent transcatheter closure. Circulation. 1990;82(5):1681-1689. DOI: 10.1161/01.CIR.82.5.1681. PMID: 2225369.
Gewillig M, Brown SC, Eyskens B, et al. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 2010;10(3):428-433. DOI: 10.1510/icvts.2009.218594. PMID: 20071336.
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.
Backer CL, Deal BJ, Mavroudis C, et al. Conversion of the failed Fontan circulation. Cardiol Young. 2006;16(Suppl 1):85-91. DOI: 10.1017/S1047951106000308. PMID: 16401378.
Krishnan US, Lamour JM, Hsu DT, Kichuk MR, Donnelly C, Addonizio LJ. Management of aortic regurgitation following cardiac transplantation for hypoplastic left heart syndrome. J Heart Lung Transplant. 2000;19(7):665-670. DOI: 10.1016/S1053-2498(00)00108-3. PMID: 10917415.